## Elise Landais

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6311632/publications.pdf Version: 2024-02-01



FLISELANDAIS

#	Article	IF	CITATIONS
1	Cross-reactivity of glycan-reactive HIV-1 broadly neutralizing antibodies with parasite glycans. Cell Reports, 2022, 38, 110611.	6.4	3
2	Highly mutated antibodies capable of neutralizing N276 glycan-deficient HIV after a single immunization with an Env trimer. Cell Reports, 2022, 38, 110485.	6.4	4
3	Nature or nurture: Factors that influence bnAb development. Cell Host and Microbe, 2021, 29, 540-542.	11.0	2
4	A Rapid Assay for SARS-CoV-2 Neutralizing Antibodies That Is Insensitive to Antiretroviral Drugs. Journal of Immunology, 2021, 207, 344-351.	0.8	5
5	Mapping Neutralizing Antibody Epitope Specificities to an HIV Env Trimer in Immunized and in Infected Rhesus Macaques. Cell Reports, 2020, 32, 108122.	6.4	28
6	Structural basis of a shared antibody response to SARS-CoV-2. Science, 2020, 369, 1119-1123.	12.6	536
7	Vaccine elicitation of HIV broadly neutralizing antibodies from engineered B cells. Nature Communications, 2020, 11, 5850.	12.8	38
8	Systems Biology Methods Applied to Blood and Tissue for a Comprehensive Analysis of Immune Response to Hepatitis B Vaccine in Adults. Frontiers in Immunology, 2020, 11, 580373.	4.8	28
9	A V <sub>H</sub> 1-69 antibody lineage from an infected Chinese donor potently neutralizes HIV-1 by targeting the V3 glycan supersite. Science Advances, 2020, 6, .	10.3	19
10	Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model. Science, 2020, 369, 956-963.	12.6	1,287
11	Rapid and Focused Maturation of a VRC01-Class HIV Broadly Neutralizing Antibody Lineage Involves Both Binding and Accommodation of the N276-Glycan. Immunity, 2019, 51, 141-154.e6.	14.3	71
12	A generalized HIV vaccine design strategy for priming of broadly neutralizing antibody responses. Science, 2019, 366, .	12.6	172
13	Immunogenicity of RNA Replicons Encoding HIV Env Immunogens Designed for Self-Assembly into Nanoparticles. Molecular Therapy, 2019, 27, 2080-2090.	8.2	58
14	An MPER antibody neutralizes HIV-1 using germline features shared among donors. Nature Communications, 2019, 10, 5389.	12.8	44
15	Coevolution of HIV-1 and broadly neutralizing antibodies. Current Opinion in HIV and AIDS, 2019, 14, 286-293.	3.8	20
16	The human naive B cell repertoire contains distinct subclasses for a germline-targeting HIV-1 vaccine immunogen. Science Translational Medicine, 2018, 10, .	12.4	113
17	Co-evolution of HIV Envelope and Apex-Targeting Neutralizing Antibody Lineage Provides Benchmarks for Vaccine Design. Cell Reports, 2018, 23, 3249-3261.	6.4	52
18	HIV Envelope Glycoform Heterogeneity and Localized Diversity Govern the Initiation and Maturation of a V2 Apex Broadly Neutralizing Antibody Lineage. Immunity, 2017, 47, 990-1003.e9.	14.3	90

Elise Landais

#	Article	IF	CITATIONS
19	An HIV-1 antibody from an elite neutralizer implicates the fusion peptide as a site of vulnerability. Nature Microbiology, 2017, 2, 16199.	13.3	144
20	Early Antibody Lineage Diversification and Independent Limb Maturation Lead to Broad HIV-1 Neutralization Targeting the Env High-Mannose Patch. Immunity, 2016, 44, 1215-1226.	14.3	138
21	Broadly Neutralizing Antibody Responses in a Large Longitudinal Sub-Saharan HIV Primary Infection Cohort. PLoS Pathogens, 2016, 12, e1005369.	4.7	241
22	Toward a more accurate view of human B-cell repertoire by next-generation sequencing, unbiased repertoire capture and single-molecule barcoding. Scientific Reports, 2014, 4, 6778.	3.3	95
23	New Design of MHC Class II Tetramers to Accommodate Fundamental Principles of Antigen Presentation. Journal of Immunology, 2009, 183, 7949-7957.	0.8	54
24	Highly Mutated Antibodies Capable of Neutralizing N276-Glycan Deficient HIV after a Single Immunization with an Env Trimer. SSRN Electronic Journal, 0, , .	0.4	0